Breaking News

Tweet TWEET

Burrill Securities Launches Institutional Breakthrough Series

Burrill Securities Launches Institutional Breakthrough Series 
Inaugural Event in New York City to Focus on Gene Therapy 
NEW YORK, NY -- (Marketwired) -- 04/29/13 --  Gene therapy holds the
promise of correcting genetic defects by providing a novel, one-time
treatment, or by obviating the need for further chronic protein
therapy. Burrill Securities today announced its inaugural
Institutional Investor Breakthrough Series: Technology Shaping
Tomorrow's Healthcare, which will focus on gene therapy. 
While the concept of therapeutic gene modification arose more than
forty years ago, with the first human subject treated in 1980, it
took this long for the field to generate robust, lasting clinical
impact with attractive safety profiles in numerous indications.  
"With the European approval of Glybera, the first gene therapy
approved in the western world, we are at an exciting time for this
emerging sector," says Stephen Hurly, CEO of Burrill Securities.
"We've seen waves of enthusiasm toward gene therapy surge and then
quickly recede with high profile setbacks. This meeting will examine
what's different now and why Big Pharma and Big Biotech have growing
interests in the area." 
Scientific founders and executives representing 10 companies will
complement the review of the field by providing proof-of-concept,
preclinical data, and human trial results. The symposium will include
panel discussions on valuing gene therapy and on the current
interests pharmaceutical companies have demonstrated in forging
partnerships to access such therapies. Presenters include luminaries
who helped to lay the foundation for the field and continue to
galvanize it.  
They include:
 Joern Aldag, CEO of uniQure 
 Larry Altstiel, MD, PhD,
CEO of ProVectra
 Reni Benjamin, PhD, Managing Director & Senior
Equity Research Analyst of Burrill Securities 
 G. Steven Burrill,
CEO of Burrill & Company
 Robert Coffin, MD, Founder of BioVex 
 Boro
Dropulic, PhD, MBA, Founder, President & CSO of Lentigen 
 Roger
Hajjar, MD, PhD, Co-founder of Celladon 
 Edward Lanphier, President
& CEO of Sangamo BioSciences, Inc.
 Sheila Mikhail, JD, MBA,
Co-founder of NanoCor & Asklepios 
 Elemer Piros, PhD, Managing
Director of Burrill Securities 
 R. Jude Samulski, PhD, Co-founder of
Asklepios 
 Samu
el Wadsworth, PhD, Head, Gene Therapy R&D, Sanofi
Genzyme R&D Center 
 Sue Washer, MBA, President & CEO of AGTC  
The day-long meeting will be held Tuesday, April 30 at The St. Regis
New York at 2 East 55th Street. 
The free event is open only to institutional investors. You must be
pre-registered for this event to attend. Seating is extremely
limited. Please contact Jennifer Gregoire at 925-998-2304 or
jgregoire@b-c.com.  
About Burrill Securities LLC  
Burrill Securities provides life sciences companies with access to
financial resources through global capital and a complementary blend
of financial advisory services on public and private financings and
cross-border transactions, including M&A, strategic partnerships,
spinouts, and public and private capital raising. It provides
companies enhanced access to public market investors through its
Institutional Equities business. Our team has extensive experience
and a comprehensive global network to help life sciences companies
access capital and strategic partners to build their businesses.
Burrill Securities LLC, member FINRA/SIPC is the investment banking
arm of Burrill & Company (www.burrillandco.com). 
Contact: 
Daniel Levine 
Managing Director 
Burrill & Company 
dlevine@b-c.com 
415-591-5449